*Organization & Developments: Bluebird (Archives 2014 - 2018)

Parents

2014: Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study
2015: Bluebird Bio Craters After Gene Therapy Disappoints BLUE CELG
2016: Biotech Forum Daily Digest: Can Biotech Rebound? Jefferies Says Sector Undervalued; Spotlight On Kite Pharma
2017: bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
2017: bluebird bio: This Winner Has A Bright 2018 Outlook - bluebird bio, Inc. (NASDAQ:BLUE)
2017: Kite Pharma Acquired - bluebird bio Remains Undervalued - bluebird bio, Inc. (NASDAQ:BLUE)
2017: This Small Biotech, Bluebird, Is Breaking Out On Its Celgene-Partnered Trial
2018: Bluebird Bio Impresses Yet Again With Gene Therapy Platform_seekingalpha.com
2018: Bluebird Bio Turns to Gritstone’s A.I. to Find TCR Cancer Targets